DRG Epidemiology’s coverage of asthma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of asthma for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered.
DRG Epidemiology’s asthma forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of asthma?
- In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of asthma?
- Of all people diagnosed with asthma, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of asthma over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following asthma subpopulation:
- Diagnosed prevalent cases by severity.
Note: Coverage may vary by country.
- Asthma - Epidemiology - Emerging Markets
- Key Findings
- Key Updates
- Prevalence of Diagnosed Symptomatic Asthma per 1,000 Among People of All Ages in 2018 and 2028
- Relative Sizes of the Contributing Factors to the Trend in Diagnosed Prevalent Cases of Symptomatic Asthma over the Next Ten Years
- Analysis of Diagnosed Prevalent Cases of Symptomatic Asthma in 2018 by Severity
- Number of Additional Prevalent Cases of Asthma in 2028 in the Countries Under Study due to Trends in Risk
- Diagnosed Symptomatic Prevalent Cases
- Diagnosed Symptomatic or Medically Controlled Prevalent Cases
- Diagnosed Symptomatic or Medically Controlled Prevalent Cases by History of Atopy
- Diagnosed Symptomatic and Medically Controlled Eosinophilic Prevalent Cases by Severity
- Diagnosed Symptomatic or Medically Controlled Prevalent Cases by Eosinophilic Status
- Diagnosed Symptomatic or Medically Controlled Prevalent Cases by BTS Steps
- Diagnosed Symptomatic or Medically Controlled Prevalent Cases by Severity
- Lifetime DALYs Gained
- Diagnosed Symptomatic Incident Cases
- Diagnosed Symptomatic Prevalent Cases by Severity
- Drug-Treated Cases of Asthma
- Epidemiology Data
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Asthma
- Studies Excluded from the Analysis of Asthma
- Risk/Protective Factors
- Risk/Protective Factors for Asthma
- Literature Review
Author(s): Alison Isherwood, MSc, MRes, PhD
Alison Isherwood, B.Sc., M.Res., M.Sc., Ph.D. joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a B.Sc. in Medical Microbiology, Masters by Research in the Life Sciences and a M.Sc. in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her Ph.D. in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.